Janssen Healthcare Innovation's Care4Today scores a double win at the eyeforpharma Barcelona Awards 2015

Not one, but two initiatives from Janssen Healthcare Innovation have been separately voted 'Most Valuable' at the eyeforpharma Barcelona Awards. This is the first time a single company has won on multiple fronts at this ceremony.

The eyeforpharma Barcelona Awards uniquely support pharmaceutical companies who prioritise value for patients and customers.

The Orthopaedic and Heart Health Solutions from the Care4Today range were yesterday announced as winners in the 'Most Valuable Patient' and 'Most Valuable HCP' categories, demonstrating the brand's commitment to transforming healthcare for the consumer.

Both initiatives were designed to involve and educate patients throughout their surgery, recovery and rehabilitation, improving not only the learning and experience of the patient, but relieving pressure on HCPs throughout the recovery process, reducing waiting times and creating engaged, empowered patients.

The Orthopaedic Solutions initiative, in conjunction with DePuy Synthes and Guy's & St Thomas' Hospital in London, comprises an interactive patient experience through a printed pack and interactive website to improve the journey of hip/knee replacement patients. Patient judge Heidi Floyd commented: "Guiding a patient from beginning to end of their surgical journey, stepping through all the way to end of recovery?  Magnificent.  As patients, we often are overwhelmed and unable to absorb required data while preparing for life-changing surgery.  This resource appears to be the perfect tool to enable and encourage patients to educate themselves about the intense process – at their own pace.  Health information such as this will change the future for patients and caregivers worldwide."

The winning projects were selected from hundreds of initiatives from Europe, Middle East, Africa and Asia/Pac, and announced yesterday at the 2nd annual eyeforpharma Barcelona Awards ceremony, determined by an international judging panel of senior industry experts, and patient advocates.

Favouring projects which could demonstrate a real improvement in the lives of the consumer, judge Steve Turley, Lundbeck, commented of the Heart Health Solutions programme: "this is an excellent project based on deep and meaningful insight, making a real difference for the company, HCPs, and patients". The initiative is a comprehensive cardiac rehabilitation programme which digitises health records allowing for improved referral and recruitment of patients onto cardiac rehabilitation and providing engaging and interactive exercise programmes for patients based on real-time data.

eyeforpharma Chairman Paul Simms commented: "These two awards are our most popular and are keenly fought over. For one company to win both is an incredible achievement and places Janssen Healthcare Innovation at the very pinnacle in terms of creating real value for patients and customers".

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.